Chemotherapy-Induced Hearing Loss Market

Market Overview:

The 7 major chemotherapy-induced hearing loss markets reached a value of US$ 9.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 13.3 Million by 2034, exhibiting a growth rate (CAGR) of 3.37% during 2024-2034.

The chemotherapy-induced hearing loss market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Hearing Loss Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced hearing loss (CIHL) refers to the detrimental impact of chemotherapy treatments on a patient's auditory system, leading to varying degrees of hearing impairment. The symptoms of this ailment may range from mild to severe and can include difficulty understanding speech, tinnitus (ringing in the ears), reduced sensitivity to sound, and an overall sense of muffled hearing. These indications can significantly affect a patient's quality of life and communication abilities during and after cancer treatment. Diagnosing CIHL involves a comprehensive evaluation of medical history, including the types and doses of chemotherapy drugs administered as well as their duration of treatment. Audiological assessments, such as pure-tone audiometry and speech perception tests, are also conducted to measure the extent of hearing loss and the specific frequencies or speech sounds that are affected. Monitoring the patient's hearing before, during, and after chemotherapy sessions can aid healthcare professionals track the progression of hearing loss and tailor interventions accordingly.

The increasing usage of chemotherapy drugs that affect the blood supply and circulation to the inner ear structures is primarily driving the chemotherapy-induced hearing loss market. In addition to this, the inflating utilization of effective interventions, including antioxidants and otoprotective medications, that aim to mitigate or even prevent the adverse auditory side effects associated with chemotherapy is also creating a positive outlook for the market. Moreover, the widespread adoption of audiological monitoring, as it facilitates early detection and management of hearing changes, is further bolstering the market growth. Apart from this, the rising advancements in rehabilitative audiology, encompassing hearing aids and cochlear implants, are acting as another significant growth-inducing factor. These technologies work by bypassing damaged portions of the inner ear and directly activating the auditory nerve, resulting in improved speech perception and understanding. Additionally, the growing interest in molecular and genetic research activities, aiming to understand the genetic predispositions that can lead to increased vulnerability to ototoxicity, is also augmenting the market growth. Furthermore, the emerging popularity of tele-audiology platforms, since they are designed for remote hearing assessments, especially in regions with limited access to audiological services, is expected to drive the chemotherapy-induced hearing loss market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the genital warts market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for genital warts and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the genital warts market in any manner.

Key Highlights:

• Each year, chemotherapy causes an estimated half a million cases of hearing loss.
• The prevalence of hearing loss following exposure to cisplatin and/or carboplatin is 43%.
• Cisplatin chemotherapy regimens tend to represent the most consistently documented risk, with 40-80% of adult and 50% of pediatric recipients reporting hearing loss.
• This condition is more common in young children than in older children, and it emerges early in therapy.

Drugs:

• PEDMARK is a prescription drug used to reduce the risk of hearing loss in patients 1 month of age and older who are taking cisplatin for solid tumors (cancer) that have not disseminated to other areas of the body. It is administered as a 15-minute infusion 6 hours following cisplatin injection.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chemotherapy-induced hearing loss market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chemotherapy-induced hearing loss market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chemotherapy-induced hearing loss marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chemotherapy-induced hearing loss market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chemotherapy-induced hearing loss market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chemotherapy-induced hearing loss market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chemotherapy-induced hearing loss across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chemotherapy-induced hearing loss by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chemotherapy-induced hearing loss by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chemotherapy-induced hearing loss across the seven major markets?
• What is the size of the chemotherapy-induced hearing loss patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chemotherapy-induced hearing loss?
• What will be the growth rate of patients across the seven major markets?
   

Chemotherapy-Induced Hearing Loss: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chemotherapy-induced hearing loss drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced hearing loss market?
• What are the key regulatory events related to the chemotherapy-induced hearing loss market?
• What is the structure of clinical trial landscape by status related to the chemotherapy-induced hearing loss market?
• What is the structure of clinical trial landscape by phase related to the chemotherapy-induced hearing loss market?
• What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced hearing loss market?